Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
239.38B
Market cap239.38B
Price-Earnings ratio
26.35
Price-Earnings ratio26.35
Dividend yield
2.59%
Dividend yield2.59%
Average volume
3.15M
Average volume3.15M
High today
$414.78
High today$414.78
Low today
$406.42
Low today$406.42
Open price
$408.30
Open price$408.30
Volume
765.83K
Volume765.83K
52 Week high
$418.40
52 Week high$418.40
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $414.37, with a market capitalization of 239.38B. The stock trades at a price-to-earnings (P/E) ratio of 26.35 and offers a dividend yield of 2.59%.

On 2026-08-10, Amgen(AMGN) stock traded between a low of $406.42 and a high of $414.78. Shares are currently priced at $414.37, which is +2.0% above the low and -0.1% below the high.

The Amgen(AMGN)'s current trading volume is 765.83K, compared to an average daily volume of 3.15M.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $418.40 at its peak.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $418.40 at its peak.

AMGN News

24/7 Wall St. 50m
The “Set It & Forget It” Stocks I’d Want to Own

The “Set It & Forget It” Stocks I’d Want to Own By Vandita Jadeja Published Aug 10, 1:00PM EDT Quick Read SBAC tops the group at a 2.58% yield, while JNJ's 64...

The “Set It & Forget It” Stocks I’d Want to Own
Investing.com 5h
Guggenheim raises Amgen stock price target to $388 on strong quarter - Investing.com

...

Guggenheim raises Amgen stock price target to $388 on strong quarter - Investing.com
TipRanks 6h
Amgen price target raised to $388 from $343 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Amgen (AMGN) to $388 from $343 and keeps a Neutral rating on the shares after updating the firm...

Analyst ratings

46%

of 35 ratings
Buy
40%
Hold
45.7%
Sell
14.3%

More AMGN News

24/7 Wall St. 14h
How to Build $13,000 a Month in Dividend Income From Three Income Buckets

How to Build $13,000 a Month in Dividend Income From Three Income Buckets By Michael Williams Published Aug 9, 11:34PM EDT Quick Read Reaching $156,000 annual...

How to Build $13,000 a Month in Dividend Income From Three Income Buckets
TipRanks 18h
Amgen Earnings Call Highlights New Growth Engines

Amgen Inc ((AMGN)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools with TipRa...

Nasdaq 4d
Upcoming Dividend Run For AMGN?

This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts featu...

Upcoming Dividend Run For AMGN?
Simply Wall St 5d
Amgen Could Be 8% Overvalued Following Raised 2026 Guidance

Amgen (AMGN) stock is back in focus after the company beat Wall Street expectations in its second quarter 2026 report and raised full year revenue and earnings...

Amgen Could Be 8% Overvalued Following Raised 2026 Guidance
TipRanks 5d
Amgen price target raised to $400 from $390 at Wells Fargo

Wells Fargo analyst Mohit Bansal raised the firm’s price target on Amgen (AMGN) to $400 from $390 and keeps an Equal Weight rating on the shares. The firm notes...

Nasdaq 6d
Amgen Q2 Earnings Call Highlights

Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pre...

Amgen Q2 Earnings Call Highlights
The Wall Street Journal 6d
Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment

Amgen said it was halting the development of AMG 513, a potential obesity treatment currently in a phase 1 study. deena beasley / Reuters Amgen AMGN 2.94 %incr...

Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.